The modified market cap-weighted index tracks the performance of the largest and most liquid US-listed companies that derive at least 50% of their revenues from pharmaceuticals. The pure-play index contains only companies which are engaged primarily engaged in research (incl. research contractors) and development as well as production, marketing and sales of pharmaceuticals. Pharmacies are excluded. The MVIS US Listed Pharmaceutical 25 Index (MVPPH) has been licensed to underlie financial products with currently USD 253.6 million in assets under management.
Full MCap of at least 150 mln USD. Three month average-daily-trading volume of at least 1 mln USD at a review and also at the previous two reviews. At least 250,000 shares traded per month over the last six months at a review and also at the previous two reviews.
Companies have to generate at least 50% revenues from pharmaceuticals.
Company weightings are capped at 20%.
1,487.10 - 2,196.10
2,166.91 - 3,236.61
1,763.80 - 2,649.55
MVIS US Pharmaceutical 25 Price Index
MVIS US Pharmaceutical 25 Total Return Net Index
MVIS US Pharmaceutical 25 Total Return Gross Index
NEWS & RESEARCH
Gain access to all Index Data and receive updates on market developments, index news and corporate announcements.